DarioHealth Corp. (NASDAQ:DRIO) CEO Sells $22,919.00 in Stock

DarioHealth Corp. (NASDAQ:DRIO) CEO Erez Raphael sold 1,300 shares of DarioHealth stock in a transaction that occurred on Thursday, July 15th. The stock was sold at an average price of $17.63, for a total value of $22,919.00. Following the completion of the transaction, the chief executive officer now directly owns 943,299 shares in the company, valued at $16,630,361.37. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of DRIO stock opened at $16.64 on Thursday. The business has a fifty day moving average price of $18.86. DarioHealth Corp. has a twelve month low of $6.85 and a twelve month high of $31.85.

DarioHealth (NASDAQ:DRIO) last issued its quarterly earnings results on Sunday, May 16th. The company reported ($0.92) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.93) by $0.01. The company had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $3.66 million. DarioHealth had a negative return on equity of 74.88% and a negative net margin of 370.22%. As a group, analysts predict that DarioHealth Corp. will post -3.3 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Dorsey Wright & Associates purchased a new stake in DarioHealth in the first quarter worth $29,000. Focused Wealth Management Inc purchased a new stake in DarioHealth in the first quarter worth $32,000. Morgan Stanley grew its stake in DarioHealth by 219.2% in the first quarter. Morgan Stanley now owns 3,543 shares of the company’s stock worth $68,000 after purchasing an additional 2,433 shares during the period. Solstein Capital LLC bought a new stake in DarioHealth in the first quarter worth $89,000. Finally, UBS Group AG boosted its holdings in DarioHealth by 48.2% in the first quarter. UBS Group AG now owns 5,476 shares of the company’s stock worth $106,000 after acquiring an additional 1,782 shares in the last quarter. 35.18% of the stock is currently owned by institutional investors.

Several equities analysts have recently issued reports on the company. Stifel Nicolaus reduced their target price on DarioHealth from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 18th. Cowen assumed coverage on DarioHealth in a research note on Thursday, April 22nd. They set an “outperform” rating and a $31.00 target price on the stock. TheStreet raised DarioHealth from a “d+” rating to a “c-” rating in a research note on Thursday, July 1st. Finally, Alliance Global Partners reduced their target price on DarioHealth from $18.25 to $15.25 and set a “neutral” rating on the stock in a research note on Monday, May 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. DarioHealth currently has a consensus rating of “Buy” and an average target price of $26.38.

About DarioHealth

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine.

See Also: How to calculate compound interest

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.